Article
Mesenchymal stromal cell therapy reduces lung inflammation and vascular remodeling and improves hemodynamics in experimental pulmonary arterial hypertension
Registro en:
MENDONÇA, Lucas de; et al. Mesenchymal stromal cell therapy reduces lung inflammation and vascular remodeling and improves hemodynamics in experimental pulmonary arterial hypertension. Stem Cell Research & Therapy, v.8:220, 15p, 2017.
1757-6512
10.1186/s13287-017-0669-0
Autor
Mendonça, Lucas de
Felix, Nathane S.
Blanco, Natália G.
Silva, Jaqueline S. da
Ferreira, Tatiana P.
Abreu, Soraia C.
Cruz, Fernanda F.
Rocha, Nazareth
Silva, Patrícia M.
Martins, Vanessa
Capelozzi, Vera L.
Zapata-Sudo, Gizele
Rocco, Patricia R.M.
Silva, Pedro L.
Resumen
Experimental research has reported beneficial effects of mesenchymal stromal cell (MSC) therapy in pulmonary arterial hypertension (PAH). However, these studies either were based on prophylactic protocols or assessed basic remodeling features without evaluating possible mechanisms. We analyzed the effects of MSC therapy on lung vascular remodeling and hemodynamics and its possible mechanisms of action in monocrotaline (MCT)-induced PAH.